A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer

Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 RAS mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with KRAS-mutant colorectal cancer. Methods: In the...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Roth, Kasmira Claire Wilson, Robert George Ramsay, Catherine Mitchell, Shienny Sampurno, Toan Duc Pham, Joseph Cherng Huei Kong, Stephen Q. Wong, Alexander Graham Heriot, Sanjeev Deva, Matthew Burge, Cecilie Sverdrup, Anne-Sophie Moller, Lukasz Kuryk, Jon Amund Eriksen, Magnus Jaderberg, John Raymond Zalcberg, Michael Michael
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Heliyon
Subjects:
Colorectal cancer
Cancer vaccine
KRAS
TG02
GM-CSF
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024173951
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024173951

Similar Items